Science
Mechanism of Action
Upon topical application, Myristyl Nicotinate penetrates the epidermis, where it is precisely converted into nicotinic acid. This active form subsequently diffuses into skin cells and transforms into nicotinamide adenine dinucleotide (NAD). NAD is hypothesized to stimulate poly(ADP-ribose) polymerase-1 (PARP-1), thereby promoting enhanced skin cell turnover, epidermal differentiation, and robust skin barrier function. Furthermore, it supports improved microcirculation, stimulates collagen synthesis, and diminishes the appearance of fine lines and wrinkles. The prodrug design ensures the therapeutic effects of niacin are delivered without the characteristic flushing.
Research
Clinical Evidence
High confidence5%
Key findings
- 01 A 5% topical cream demonstrated improvements in skin barrier function, mitigated signs of sun damage, reduced the incidence of atopic dermatitis, and limited the progression of actinic skin damage.
- 02 Studies indicate it enhances the skin's protective barrier, leading to superior hydration and reduced transepidermal water loss. It also visibly diminishes fine lines and wrinkles through boosted ceramide production and stimulation of elastin and collagen synthesis.
Transparency
Dusting Analysis
Myristyl Nicotinate is a well-researched active ingredient with a defined prodrug mechanism and demonstrated efficacy in improving skin barrier function, hydration, and mitigating aging signs at a 5% concentration. Its complex biochemical conversion and broad benefits distinguish it from ingredients used primarily for marketing "dusting."
The Formula
Formulation
Stability
Formulations exhibit robust stability at room temperature for 3 years, with less than 0.05% conversion to free nicotinic acid, which is critical to avoid skin flushing. It is imperative to avoid exposure to temperatures exceeding 80°C.
Conflicts
- potassium permanganate (if used with propylene glycol as a solvent)
Safety
Safety Profile
The Cosmetic Ingredient Review (CIR) has not yet evaluated Myristyl Nicotinate. A Phase I clinical trial is currently underway (ClinicalTrials.gov NCT00000419) to comprehensively assess its safety, tolerability, and potential for local or systemic toxicity over a one-month period. Its formulation stability, crucial for preventing flushing, remains high, with less than 0.05% conversion to nicotinic acid over 3 years at room temperature.
Your Skin
Skin Compatibility
Our Assessment
Verdict
Myristyl Nicotinate is a valuable prodrug form of niacin, adept at fortifying the skin barrier, enhancing hydration, and addressing visible signs of aging without the common flushing reaction, making it highly compatible with a wide range of skin types.
Related
Similar Ingredients
Finding similar ingredients…